REPRIEVE Trial

09/28/2023

¿Se pregunta cómo las personas con VIH pueden proteger la salud de su corazón? ¡Únase a nosotros para un foro comunitario virtual mañana a las 11:00 a. m., hora del este! https://www.reprievetrial.org/for-participants/community-forum/

09/20/2023

We are excited to share that REPRIEVE will be hosting two Community Forums to review the primary results of REPRIEVE during the month of September! These will be held on Thursday, September 21st at 1:00 PM ET (English) and Friday, September 29th at 11:00 AM ET (Spanish).

Join us tomorrow at 1:00 PM ET to learn about REPRIEVE and what the trial's results mean for people with HIV! For more information, visit our website: https://www.reprievetrial.org/for-participants/community-forum/

09/12/2023

Thanks to lifesaving drugs, people with HIV are proudly achieving aging milestones. Now, researchers have been searching for ways to keep this community healthier in their later years. Read more in The New York Times: https://www.nytimes.com/2023/09/10/health/hiv-aging-statins.html
AIDS Clinical Trials Group National Heart, Lung, and Blood Institute (NHLBI) National Institute of Allergy and Infectious Diseases (NIAID)

07/25/2023

The REPRIEVE Trial demonstrates that pitavastatin lowers the incidence rate of heart disease events by 35% in people with HIV. Read the results in :

Original Article from The New England Journal of Medicine — Pitavastatin to Prevent Cardiovascular Disease in HIV Infection

04/11/2023

: Taking a daily statin medication has been found to reduce the excess risk of cardiovascular disease (CVD) among people living with HIV in , the first large-scale clinical trial testing a CVD preventive strategy in this population. Read the full NIH press release here:

Premature heart disease and other chronic conditions have emerged as leading causes of morbidity and mortality.

03/08/2021

The REPRIEVE Trial is excited to be sharing some preliminary baseline findings at CROI 2021! If you're attending virtual CROI this year, be sure to check out these 4 Science Spotlight presentations from the REPRIEVE team:

12/01/2020

In his statement, Dr. Fauci highlights how far we have come, how far we have yet to go, and acknowledges the important work of the REPRIEVE Trial. We are grateful to be a part of the continued HIV research efforts of the National Institutes of Health (NIH) and National Institute of Allergy and Infectious Diseases (NIAID).
Click the link below to read the full statement from the NIH.

Today on World AIDS Day, we reflect both on the remarkable progress that has been made against HIV as well as the considerable challenges that remain. We now have highly effective HIV treatment and prevention methods, and work is underway to address the remaining challenges in delivering these tools...

12/01/2020

On this we are reminded of the resilience of the HIV community, living through the HIV epidemic and the COVID-19 pandemic. The strength of the HIV community provides a beacon of hope and reminds us that we will get through this together.

Thank you to our community of participants, site investigators and staff who have remained dedicated to the safety of one another and the important research of the REPRIEVE Trial.

10/26/2020

We are excited to contribute to all of the important ongoing COVID-19 research. Watch the video below by our colleagues at National Heart, Lung, and Blood Institute (NHLBI) to learn how the REPRIEVE trial plans to examine COVID-19 in our global cohort of people with HIV.

09/18/2020

National HIV/AIDS & Aging Awareness Day reminds us that although ART has been successful at prolonging the lives of , people aging with HIV often experience a number of other comorbidities - which is why findings from will be so important

09/03/2020

We know six manuscripts, plus an introduction piece, is a lot to read... So we summarized the findings for you! Click the link below to read summaries of findings from the baseline manuscripts published in The Journal of Infectious Diseases!

Summaries of articles in: Critical Comorbidities in the Modern Antiretroviral Era: Baseline Demographic, Metabolic, and Immune

08/19/2020

Thank you to our REPRIEVE team and participants at CWRU AIDS Clinical Trials Unit!! REPRIEVE would not be a success without you - and all of our amazing clinical research sites and participants!

With 7,770 participants enrolled in 12 countries across five continents, the REPRIEVE study is evaluating the ability of a statin medication to reduce the risk of heart disease among people with HIV. By leveraging data collected from this diverse group of study participants, researchers also are lea...